Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients

FEMS Immunology and Medical Microbiology

Volumn 37, Issue 2-3, 2003, Pages 161-166

  Mansouri, Erfan ^a   Blome Eberwein, Sigrid ^c   Gabelsberger, Josef ^b   Germann, Günter ^c   Von Specht, Bernd Ulrich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MediGene AG   (Germany)

^c NONE

Author keywords

Burn; Infectious disease; Outer membrane protein; Pseudomonas aeruginosa; Vaccine

Indexed keywords

ANTIBODY; OUTER MEMBRANE PROTEIN; PSEUDOMONAS VACCINE; RECOMBINANT VACCINE; TETANUS ANTIBODY; TETANUS TOXOID;

ADULT; ANTIBODY DETECTION; ARTICLE; BODY SURFACE; BURN; BURN INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; MALE; PATIENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEROCONVERSION; SEROLOGY;

EID: 0037756803     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00072-5     Document Type: Article

References (29)

1. Alexander J.W., Fisher M.W. Immunization against Pseudomonas infection after thermal injury. J. Infect. Dis. 130:1974;152-158.
2. Cohen J. Naked DNA points way to vaccines. Science. 259:1993;1691-1692.
3. Donnelly J.J., Ulmer J.B., Liu M.A. Immunization with polynucleotides. Immunologist. 2:1994;20-26.
4. Douglas M.W., Mulholland K., Denyer V., Gottlieb T. Multi-drug resistant Pseudomonas aeruginosa outbreak in a burn unit - an infection control study. Burns. 27:2001;131-135.
5. Duchêne M., Barron C., Schweizer A., von Specht B.U., Domdey H. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning sequence, and expression in Escherichia coli. J. Bacteriol. 171:1989;30-4137.
6. Duchêne M., Schweizer A., Lottspeich F., Krauss G., Marget M., Vogel K., von Specht B.U., Domdey H. Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene. J. Bacteriol. 170:1988;155-162.
7. Finke M., Duchêne M., Eckhardt A., Domdey H., von Specht B.U. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infect. Immun. 58:1990;2241-2244.
8. Finke M., Muth G., Reichhelm T., Thoma M., Duchêne M., Hungerer K.D., Domdey H., von Specht B.U. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies. Infect. Immun. 59:1991;51-1254.
9. Gabelsberger J., Knapp B., Bauersachs S., Lenz U., von Specht B.U., Domdey H. A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa. Behring Inst. Mitt. 98:1997;302-314.
10. Gilleland H.E. Jr., Gilleland L.B., Matthews-Greer J.M. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in rats. Infect. Immun. 56:1988;1017-1022.
11. Gilleland H.E. Jr., Hughes E.E., Gilleland L.B., Matthews-Greer J.M., Staczek J. Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of Pseudomonas aeruginosa. Curr. Microbiol. 31:1995;279-286.
12. Gilleland H.E. Jr., Parker M.G., Matthews J.M., Berg R.D. Use of purified outer membrane protein F (porin) of Pseudomonas aeruginosa as a protective vaccine in mice. Infect. Immun. 44:1984;49-54.
13. Gilleland L.B., Gilleland H.E. Jr. Synthetic peptides representing two protective, linear B cell epitopes of outer membrane protein F of Pseudomonas aeruginosa elicit whole-cell-reactive antibodies that are functionally pseudomonad specific. Infect. Immun. 63:1995;2347-2351.
14. Hancock R.E.W. Intrinsic antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 18:1986;653-656.
15. Hancock R.E.W., Wong R. Potential of protein OprF of Pseudomonas in bivalent vaccines. Behring Inst. Mitt. 98:1997;83-290.
16. Jones R.J., Roe E.A., Gupta J.L. Controlled trials of a polyvalent Pseudomonas vaccine in burns. Lancet. 2:1979;977-983.
17. Kim D.K., Kim J.J., Kim J.H., Woo Y.M., Kim S., Yoon D.W., Choi C.S., Kim I., Park W.J., Lee N., Jung S.B., Ahn B.Y., Nam S.W., Yoon S.M., Choi W.J. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine. 19:2001;1274-1283.
18. Lee N.G., Jung S.B., Ahn B.Y., Kim Y.H., Kim J.J., Kim D.K., Kim I.S., Yoon S.M., Nam S.W., Kim H.S., Park W.J. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Vaccine. 18:2000;1952-1961.
19. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.-D., Gilleland H.E. Jr., Staczek J., Domdey H., von Specht B.U. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 67:1999;1461-1470.
20. Matthews-Greer J.M., Gilleland H.E. Jr. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J. Infect. Dis. 155:1987;1282-1291.
21. Miller J.M., Spilsbury J.F., Jones R.J., Roe E.A., Lowbury E.J.L. A new polyvalent Pseudomonas vaccine. J. Med. Microbiol. 10:1977;19-27.
22. Miller J.M., Spilsbury J.F., Jones R.J., Roe E.A., Lowbury E.J.L. A new polyvalent Pseudomonas vaccine. J. Med. Microbiol. 10:1977;19-27.
23. Mutharia L.M., Nicas T.I., Hancock R.E.W. Outer membrane proteins of P. aeruginosa serotype strains. J. Infect. Dis. 146:1982;770-779.
24. Park W.J., Cho Y.J., Kim Y.G., et al. Active and passive protective effect of CFC-101 (Pseudomonas vaccine) in mice. J. Appl. Pharmacol. 2:1994;326-330.
25. Schwacha M.G., Avala A., Cioffi W.G., Bland K.I., Chaudry I.H. Role of protein kinase C in cyclic AMP-mediated suppression of T-lyphocyte activation following burn injury. Biochim. Biophys. Acta. 1455:1999;45-53.
26. Tobiasen J., Hiebert J., Edlich R. Prediction of burn mortality. Surg. Gynecol. Obstet. 154:1982;711-714.
27. von Specht B.U., Knapp B., Muth G., Bröker M., Hungerer K.-D., Diehl K.D., Massarrat K., Seemann A., Domdey H. Protection of immunocompromised mice against lethal infection with P. aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect. Immun. 63:1995;1855-1861.
28. von Specht B.U., Strigl G., Ehret W., Brendel W. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection. Infection. 15:1987;408-412.
29. Zedler S., Bone R.C., Baue A.E., von Donnersmark G.H., Faist E. T-cell reactivity and its predictive role in immunosuppression after burns. Crit. Care Med. 27:1999;66-67.